Lista de obras -

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

artículo científico publicado en 2017

A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group

scientific article published on 09 August 2019

Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

artículo científico publicado en 2015

Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome

artículo científico publicado en 2017

Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule

artículo científico publicado en 2011

Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience

artículo científico publicado en 2018

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences

artículo científico publicado en 2020

Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report

artículo científico publicado en 2017

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

artículo científico publicado en 2015

Clonal evolution in therapy-related neoplasms.

artículo científico publicado en 2017

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

artículo científico publicado en 2015

Epigenetic changes in therapy-related MDS/AML.

artículo científico publicado en 2009

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes

scientific article published on 10 July 2018

Fanconi anemia gene variants in therapy-related myeloid neoplasms.

artículo científico publicado en 2015

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

artículo científico publicado en 2017

Fungaemia in haematological malignancies: SEIFEM-2015 survey

scientific article published on 07 March 2019

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.

artículo científico publicado en 2012

Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.

artículo científico publicado en 2015

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

scientific article published on 08 April 2020

Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?

artículo científico publicado en 2016

Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study

artículo científico publicado en 2022

Mastocytosis: One Word for Different Diseases

scientific article published on 29 October 2018

Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms

artículo científico publicado en 2014

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)

artículo científico publicado en 2018

Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.

artículo científico publicado en 2012

New treatments for myelodysplastic syndromes

artículo científico publicado en 2010

Outcome of therapy-related myeloid neoplasms treated with azacitidine

artículo científico publicado en 2012

Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes

artículo científico publicado en 2008

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

artículo científico publicado en 2014

Primary plasma cell leukemia followed by testicular plasmacytoma

artículo científico publicado en 2011

Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin

artículo científico publicado en 2014

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

artículo científico publicado en 2016

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.

artículo científico publicado en 2014

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Reg

artículo científico publicado en 2013

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

artículo científico publicado en 2011

SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.

artículo científico publicado en 2017

SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

artículo científico publicado en 2014

Similarities and differences between therapy-related and elderly acute myeloid leukemia.

artículo científico publicado en 2011

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes

artículo científico publicado en 2018

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

artículo científico publicado en 2015

The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes

scientific article published on 01 November 2013

Therapy-related myeloid neoplasms: clinical perspectives

scientific article published on 17 September 2018

Treatment of Low-Blast Count AML using Hypomethylating Agents

artículo científico publicado en 2017

Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.

artículo científico publicado en 2015

Why methylation is not a marker predictive of response to hypomethylating agents.

scientific article published on April 2014

Lista de obras de

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group

Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome

Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule

Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences

Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

Clonal evolution in therapy-related neoplasms.

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

Epigenetic changes in therapy-related MDS/AML.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes

Fanconi anemia gene variants in therapy-related myeloid neoplasms.

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

Fungaemia in haematological malignancies: SEIFEM-2015 survey

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.

Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?

Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study

Mastocytosis: One Word for Different Diseases

Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)

Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.

New treatments for myelodysplastic syndromes

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

Primary plasma cell leukemia followed by testicular plasmacytoma

Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Reg

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.

SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Similarities and differences between therapy-related and elderly acute myeloid leukemia.

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes

Therapy-related myeloid neoplasms: clinical perspectives

Treatment of Low-Blast Count AML using Hypomethylating Agents

Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.

Why methylation is not a marker predictive of response to hypomethylating agents.